Biotest and SteinCares Enhance Access to Hemophilia Treatment in Latin America

Biotest AG has announced a strategic distribution agreement with SteinCares to introduce Haemoctin®, a plasma-derived Factor VIII product, in select Latin American countries including Chile, Colombia, and Mexico. This collaboration aims to address hemophilia treatment gaps and improve access to high-quality care in the region.

Haemoctin® offers a reliable alternative for hemophilia A patients, characterized by its efficacy, purity, and safety. With approximately 40% of diagnosed patients lacking adequate prophylactic treatment, this partnership is a pivotal step toward expanding Biotest's presence in Latin America and advancing patient care.

The agreement highlights the importance of economic and strategic stability amidst regional political challenges, emphasizing a mutual commitment to enhancing healthcare access and cost-effectiveness.